/
AVXL
$2.60-$0.02 (-0.76%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$242.8M
93M shares
52-week range
$2.41 – $13.99
2% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.83%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-20.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $13.3M | $22.3M | $25.2M | $33.0M | $37.9M | $43.7M | $41.8M | $37.6M |
| Operating income | $0 | $0 | $0 | −$42.0M | −$51.0M | −$55.8M | −$52.9M | −$51.4M |
| EBITDA | −$19.1M | −$28.9M | −$31.1M | −$37.6M | −$47.6M | −$46.5M | −$43.0M | −$46.4M |
| Net income | −$17.5M | −$26.3M | −$26.3M | −$37.9M | −$48.0M | −$47.5M | −$43.0M | −$46.4M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.39 | -0.54 | -0.45 | -0.54 | -0.62 | -0.60 | -0.52 | -0.54 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $776M | $-0.33 | $-0.33–$-0.33 | 1 |
| 2027 | $1.2B | $-0.55 | $-0.55–$-0.55 | 1 |
| 2028 | $349M | $2.27 | $2.27–$2.27 | 1 |
| 2029 | $713M | $4.66 | $4.66–$4.66 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.17
Price
$2.60
Implied downside
-55%
Peer comparison
Anavex Life Sciences
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
www.anavex.com- Employees
- 34
- IPO / List date
- Aug 2, 2006
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds AVXL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 276,800 | $849.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2015-10-07 | 1-for-4reverse |
Recent trades on TradeandTell
No one on the platform has traded AVXL yet.
